MDAIHIGH SIGNALFINANCIAL10-K

MDAI shows a stark contradiction between dramatically improved cash position and liquidity (+196% cash increase) versus severely deteriorating operational performance with revenue declining 34% and operating losses worsening 31%.

The massive cash infusion suggests significant dilutive equity financing (share count increased 26% from 25.3M to 31.8M shares), which provided short-term financial stability but at the cost of substantial shareholder dilution. The company's core business appears to be contracting rapidly with revenue falling from $29.6M to $19.6M while operating losses increased, creating questions about the sustainability of the business model and how long the new cash will last at current burn rates.

Comparing 2026-03-25 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

MDAI's financials present a mixed but concerning picture - while cash and equivalents surged 196% to $15.4M and total assets grew 77%, this came at the expense of significant equity dilution with share count rising 26%. The operational story is troubling, with revenue declining 34% from $29.6M to $19.6M, gross profit falling 33%, and operating losses worsening from -$6.6M to -$8.6M despite the revenue decline. The improved net loss of -$7.6M versus -$15.3M appears driven by non-operating factors rather than business improvement, suggesting the cash infusion provides temporary relief but doesn't address underlying operational challenges.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+196.2%
$5.2M$15.4M

Cash position surged 196.2% — strong cash generation or capital raise providing significant financial cushion.

Inventory
Balance Sheet
+97.2%
$425K$838K

Inventory surged 97.2% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.

Current Assets
Balance Sheet
+92.2%
$10.1M$19.5M

Current assets grew 92.2% — improving short-term liquidity or inventory/receivables build.

Total Assets
Balance Sheet
+77%
$12.1M$21.4M

Asset base grew 77% — expansion through organic growth, acquisitions, or capital deployment.

Net Income
P&L
+50.6%
-$15.3M-$7.6M

Net income grew 50.6% — bottom-line growth signals improving overall business health.

Accounts Receivable
Balance Sheet
-49.4%
$2.5M$1.3M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Total Liabilities
Balance Sheet
+40.2%
$19.3M$27.1M

Liabilities grew 40.2% — significant increase in debt or obligations, assess impact on financial flexibility.

Revenue
P&L
-33.6%
$29.6M$19.6M

Revenue declined 33.6% — significant demand weakness or market share loss warrants investigation.

Gross Profit
P&L
-32.8%
$13.3M$8.9M

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

Operating Income
P&L
-30.7%
-$6.6M-$8.6M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

LANGUAGE CHANGES
NEW — 2026-03-25
PRIOR — 2025-03-31
ADDED
As of March 23, 2026, there were 31,823,895 shares of Common Stock, $0.0001 par value per share, issued and outstanding.
Our BARDA contract is not guaranteed to be fully awarded or extended.
If our Common Stock does not maintain a certain price or market capitalization level or otherwise, Nasdaq may delist our securities from trading on its exchange, which could limit investors ability to make transactions in our securities and subject us to additional trading restrictions.
We are an AI company focused on predictive medical diagnostics.
In 2026, we hope that our full DeepView System may achieve Class II medical device designation with the United States Food and Drug Administration (FDA) via the De Novo application the Company submitted in June of 2025.
+7 more — sign up free →
REMOVED
As of March 26, 2025, there were 25,317,196 shares of Common Stock, $0.0001 par value per share, issued and outstanding.
Our BARDA contract is not guaranteed to be completed or extended.
Nasdaq may delist our securities from trading on its exchange, which could limit investors ability to make transactions in our securities and subject us to additional trading restrictions.
iii The price of our Common Stock and Warrants may be volatile.
Overview We are an Artificial Intelligence ( AI ) company focused on predictive medical diagnostics.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →